Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Gilead Sciences (GILD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Gilead Sciences is one of 760 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for GILD's full-year earnings has moved 3.45% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, GILD has returned 6.53% so far this year. Meanwhile, the Medical sector has returned an average of 3.06% on a year-to-date basis. This shows that Gilead Sciences is outperforming its peers so far this year.
Breaking things down more, GILD is a member of the Medical - Biomedical and Genetics industry, which includes 280 individual companies and currently sits at #106 in the Zacks Industry Rank. On average, stocks in this group have lost 2.64% this year, meaning that GILD is performing better in terms of year-to-date returns.
GILD will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
